Welcome to our dedicated page for Encision news (Ticker: ECIA), a resource for investors and traders seeking the latest updates and insights on Encision stock.
Encision Inc. (ECIA) is a medical device company based in Boulder, Colorado that designs and markets surgical instrumentation for minimally invasive procedures and owns patented Active Electrode Monitoring (AEM®) technology. The Encision news feed on Stock Titan brings together the company’s official press releases and other coverage related to its operations, financial performance, and technology.
Investors and observers can use this page to follow Encision’s quarterly and annual financial results, where the company reports product and service net revenue, gross profit, operating expenses, and net income or loss. These updates often include commentary on gross margins, material costs, operating efficiencies, and the balance between product and service revenue.
News items also cover corporate developments such as private placements of common stock, agreements with partners, and board or executive changes disclosed through press releases and SEC filings. For example, Encision has announced a Master Services Agreement with Vicarious Surgical Inc. for design services related to a robotic surgical system, as well as leadership transitions reported in 8-K filings.
Technology-focused updates highlight Encision’s AEM platform, its role in preventing dangerous stray energy burns in minimally invasive surgery, and the company’s efforts to develop new devices, including products for the ear, nose and throat (ENT) space. Commentary in these releases provides context on how Encision is addressing trends in laparoscopic and robotic surgery, collaborating with partners, and pursuing new revenue opportunities.
Use this page to review Encision’s historical and recent announcements in one place, compare narratives across reporting periods, and understand how management describes the company’s strategy, challenges, and progress over time.
Encision (OTC PINK: ECIA) reported fiscal Q3 2026 results with net sales of $1.413M and a net loss of $314k. Gross profit margin fell to 38.4% after a large inventory reserve. The company is executing a restructuring and expects reduced operating costs to be recognized in Q4.
Encision (OTC PINK: ECIA) announced Board approval to file a Form 15 with the SEC on or about January 29, 2026, to voluntarily deregister common stock under Section 12(g). Effective about 90 days after filing, SEC reporting obligations (Forms 10-K, 10-Q, 8-K) will be suspended. The company cited its size, market capitalization, and compliance costs as reasons and expects cost savings. Encision says it will continue to publish unaudited quarterly and annual results and expects its shares to remain tradable OTC under ECIA, though continued market maintenance is not guaranteed.
Encision (PK:ECIA) reported fiscal Q2 2026 results for the quarter ended September 30, 2025: total net revenue $1.53M (product $1.48M; service $46K) and a net loss $0.27M or $(0.02) per diluted share.
Compared with the prior-year quarter, product revenue fell ~10%, total revenue fell ~13%, and gross profit was $697K. Cash was $71,731 at quarter end and the company recorded proceeds of $500K from issuance of common stock year-to-date. Encision expects a new ENT device launch in Q4 and continues R&D investment.
Encision (OTC PINK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM®) Technology, has completed a $500,000 private placement of common stock. The company issued 5 million common shares at $0.10 per share to a group of investors including directors, executive officers, existing shareholders, and new investors.
The funding will support ongoing operations and the development of their new ENT Device, expected to launch in early 2026. Following the private placement, Encision's total outstanding common shares increased to 16,879,645. The issued shares are restricted and do not have registration rights.
Encision Inc. (OTC PINK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM®) Technology, reported its fiscal 2026 first quarter results ending June 30, 2025. The company posted total net revenue of $1.6 million, comprising $1.49 million in product revenue and $110,000 in service revenue. The quarter resulted in a net loss of $41,000 ($0.00 per share), compared to a net income of $22,000 in the year-ago quarter.
Key financial metrics include a product gross margin of 55%, down from 58% in the previous year's quarter. Operating expenses totaled $898,239, with significant allocations to sales and marketing ($404,601), general and administrative ($328,198), and research and development ($165,440). The company's cash position decreased to $47,918 from $257,433 at the beginning of the fiscal year.
Encision Inc. (OTC PINK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM®) Technology, reported its fiscal year 2025 results. The company posted Q4 net revenue of $1.52 million with a quarterly net loss of $47,000 ($(0.00) per share), compared to a net loss of $337,000 ($(0.03) per share) in Q4 2024.
For fiscal year 2025, Encision reported total net revenue of $6.56 million, comprising $6.22 million in product revenue and $0.34 million in service revenue. The company's net loss improved to $0.22 million ($(0.02) per share) from $0.69 million ($(0.06) per share) in FY2024. Notably, gross margin on product revenue increased to 53.8% in FY2025 from 47.6% in FY2024, driven by lower material costs and improved operational efficiency.
Encision Inc. (ECIA) reported its fiscal 2025 third quarter results ending December 31, 2024. The company posted total net revenue of $1.59 million, comprising $1.46 million in product revenue and $128,000 in service revenue, with a quarterly net loss of $24,000 or $(0.00) per diluted share.
For the nine-month period, total net revenue was $4.97 million with a net loss of $172,900 or $(0.01) per diluted share. Gross margin on product revenue improved to 54% in Q3 FY2025 from 46% in Q3 FY2024. The company is developing a new product for ENT surgery, expected to launch in the first half of FY2026.
The quarter was described as a rebuilding period, with new sales partners onboarded and internal cost reduction measures implemented, expected to show effects from Q4 onwards.
Encision Inc. (OTC PINK:ECIA) reported financial results for Q2 FY2025 ending September 30, 2024. Total net revenue was $1.75 million, down from $1.83 million in Q2 FY2024, with a quarterly net loss of $170,000 ($(0.01) per share). Product net revenue decreased to $1.65 million from $1.75 million year-over-year, while service revenue increased to $101,000. The company maintained a 47% gross margin on product revenue. For the six-month period, total revenue was $3.39 million with a net loss of $148,000. Performance was impacted by reduced surgical procedures due to hurricanes in the southeast and saline availability issues. The company plans to launch a new ENT market product in early FY2026.
Encision Inc. (OTC PINK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM) Technology, has signed a Master Services Agreement with Vicarious Surgical Inc. The agreement, effective July 8, 2024, involves Encision providing design services for elements of Vicarious' robotic surgical system.
Gregory J. Trudel, President and CEO of Encision, expressed excitement about the collaboration, highlighting the opportunity to bring best-in-class technology to surgical robotics and contribute to patient safety and clinical performance. Encision, based in Boulder, Colorado, focuses on developing surgical instrumentation that enhances patient safety and surgical performance across various minimally invasive procedures.
Encision Inc. (OTC PINK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM) Technology, reported financial results for its fiscal 2025 first quarter ended June 30, 2024. The company achieved:
- Total net revenue of $1.63 million
- Quarterly net income of $22,000 ($0.00 per diluted share)
- Product net revenue of $1.59 million
- Service net revenue of $39,000
- Gross margin on product net revenue increased to 58% from 52% in the previous year
The improved performance is attributed to higher operating efficiencies and increased selling prices. CEO Gregory Trudel highlighted the company's progress in sales channel investment and technology development, as well as efforts to create new service revenue streams.
FAQ
What is the current stock price of Encision (ECIA)?
What is the market cap of Encision (ECIA)?
